- A federally funded study will be conducted at 10 academic medical centers across the United States. To streamline oversight, the funding agency requires use of a single IRB (sIRB). Which statement accurately describes the ethical responsibilities under this model?
Answer: Each participating site remains responsible for safeguarding participants even though the sIRB provides the regulatory review
When you encounter questions about single IRB (sIRB) models in multi-site research, focus on understanding that regulatory oversight and ethical responsibility operate at different levels. The sIRB system was designed to streamline regulatory review while preserving local accountability.
Answer A correctly identifies that each participating site retains fundamental responsibility for participant safety and welfare, even when a centralized sIRB handles the regulatory review process. This reflects the principle that ethical responsibility cannot be transferred away from those directly conducting research with human subjects. Local investigators and institutions remain accountable for protocol implementation, adverse event reporting, and participant protection at their specific sites.
Answer B incorrectly suggests the sIRB assumes liability for protocol deviations. In reality, local investigators remain responsible for protocol adherence and must report deviations to both the sIRB and their own institutions. Liability cannot be transferred to a reviewing body.
Answer C is wrong because local IRBs can impose additional protections or requirements based on local regulations, institutional policies, or community standards, even after sIRB approval. The sIRB provides a regulatory floor, not a ceiling.
Answer D misunderstands informed consent requirements. Even with sIRB approval, consent documents must include site-specific contact information so participants can reach local investigators, institutional officials, or ethics committees with questions or concerns.
Remember: sIRB models centralize regulatory review for efficiency, but they never eliminate local responsibility for participant protection. Each site remains fully accountable for the ethical conduct of research within its walls.
- The ethical obligation to publish the results of this study is primarily based on which of the following principles?
Answer: Avoiding the waste of research resources and respecting participant contributions
The correct answer is A. There is a strong ethical obligation to publish the results of clinical trials, regardless of the outcome. This is based on several principles. First, it respects the contribution and altruism of the participants who exposed themselves to risk. Second, it prevents 'publication bias,' where the medical literature becomes skewed towards positive findings. Third, it prevents other researchers from wasting resources and exposing future participants to the risks of studying a drug that has already been shown to be ineffective or harmful. Suppressing negative results is a form of scientific misconduct.
B, C, and D all represent unethical considerations that conflict with the primary ethical duty to disseminate research findings honestly.
- The collection of IP addresses compromises which of the following ethical protections promised to the participants?
Answer: Anonymity
The correct answer is A. Anonymity means that there is no way for anyone, including the researcher, to link the research data to a specific individual. Confidentiality means the researcher can link the data to an individual but promises not to disclose that link. By collecting IP addresses, which can potentially be traced to an individual or location, the study is no longer truly anonymous. This is a critical ethical failure, especially given the sensitive and illegal nature of the topic being studied, as it places participants at risk.
B) Beneficence (maximizing good) and C) Justice (fairness) are not the primary principles compromised here.
D) The informed consent process would be flawed because it inaccurately promised anonymity, but the core protection that has been violated is anonymity itself.
- While writing the manuscript of a completed randomized trial, the senior author decides to omit secondary outcome data on hospital readmissions because the difference between groups was unfavorable and not statistically significant. Which practice does this decision exemplify?
Answer: Selective outcome reporting that can introduce bias and undermine research integrity
Research ethics questions on the USMLE often test your ability to identify various forms of research misconduct and understand how they compromise scientific integrity. When you encounter scenarios about authors making editorial decisions about data inclusion, focus on whether all prespecified outcomes are being reported transparently.
The scenario describes selective outcome reporting, where researchers choose to omit unfavorable results from publication. This practice introduces bias because it presents an incomplete picture of the study's findings, preventing readers from making fully informed judgments about the intervention's effectiveness. Even non-significant or unfavorable secondary outcomes should be reported as they contribute valuable information to the scientific record and help prevent publication bias in future meta-analyses.
Let's examine why the other options don't fit: B) Duplicate publication refers to publishing the same study results in multiple venues without proper disclosure, not omitting data from a manuscript. C) Gift authorship involves granting authorship to someone who didn't substantially contribute to the work - the issue here isn't about authorship assignment but data reporting. D) Fabrication involves making up false data, but in this case, the data exists and is simply being omitted rather than falsified.
For USMLE research ethics questions, remember that transparency is paramount in scientific reporting. Any deviation from complete, honest reporting of prespecified outcomes - whether favorable or unfavorable, significant or not - constitutes selective reporting bias. Watch for scenarios where authors make editorial decisions based on the favorability of results rather than scientific merit.
- The physician's statement, "I think it could really help you," has the potential to create which of the following ethical problems?
Answer: Therapeutic misconception
The correct answer is B. Therapeutic misconception occurs when research participants fail to distinguish between the goals of clinical research and ordinary clinical care. The primary goal of research is to produce generalizable knowledge, not to provide individualized treatment. The physician's statement emphasizes the potential personal benefit, which may lead the patient to incorrectly believe they are receiving a personalized treatment rather than participating in an experiment. This can compromise the validity of their informed consent.
A) There is no indication of a privacy violation.
C) Scientific misconduct involves fabrication, falsification, or plagiarism, which is not depicted here.
D) Selection bias relates to how subjects are chosen for a study, not how consent is obtained.
- This recruitment strategy is most concerning for violating which of the following principles of research ethics?
Answer: Justice
The correct answer is C. The principle of Justice, as described in the Belmont Report, requires the equitable selection of subjects. This means that the burdens and benefits of research should be distributed fairly. By targeting only affluent neighborhoods and having inconvenient appointment times, the study systematically excludes certain socioeconomic groups. This leads to a non-representative sample and places the burdens of research (e.g., risks of the vaccine) on one group while the benefits (a vaccine for a common illness) will be for all of society.
A) Beneficence refers to maximizing benefits and minimizing harms.
B) Non-maleficence means 'do no harm'.
D) Autonomy refers to respecting individuals' capacity for self-determination, primarily through informed consent. While related, the core issue here is fairness in selection.
- During a multi-center trauma trial, unconscious patients with massive hemorrhage are randomized in the ambulance to receive an experimental blood substitute or standard packed RBCs. The study was approved by an Institutional Review Board under FDA regulations allowing exception from informed consent for emergency research. Which additional condition must be satisfied to meet federal ethical requirements for this exception?
Answer: Community consultation and public disclosure about the study were conducted before enrollment began
When you encounter questions about emergency research without informed consent, think about the FDA's strict regulations that balance urgent medical needs with patient protection. This scenario involves Exception from Informed Consent for Emergency Research (EFIC), which has very specific federal requirements.
The correct answer is A because community consultation and public disclosure are mandatory EFIC requirements. Before any emergency research begins, investigators must engage the community where the study will occur through public meetings, focus groups, or other mechanisms to gather input. They must also publicly disclose the study through media, websites, or community postings. This ensures transparency and gives the community a voice in research that affects unconscious patients who cannot consent.
Option B is incorrect because surrogate consent within 24 hours is not a federal EFIC requirement. While obtaining consent when possible is encouraged, the exception specifically addresses situations where this isn't feasible.
Option C misrepresents the requirements. While eligibility must be properly documented, federal regulations don't mandate an independent physician for this documentation. The research team can determine eligibility following proper protocols.
Option D is wrong because continuing investigational treatment throughout hospitalization isn't required. Once patients regain capacity or surrogates are available, standard informed consent processes should resume, and patients can withdraw from the study.
Remember that EFIC questions on Step 1 often test whether you know the specific federal safeguards: community consultation, public disclosure, IRB approval with specific findings, and data safety monitoring. These protect vulnerable emergency patients while allowing potentially life-saving research.
- The inclusion of a placebo arm in this trial is ethically problematic because it conflicts with the principle that participants should not be denied which of the following?
Answer: Access to a known effective therapy
The correct answer is A. It is generally considered unethical to use a placebo control group when a known, effective therapy exists for a condition, especially a serious one. Denying participants an effective treatment and giving them a placebo exposes them to preventable harm (in this case, continued severe migraines). The Declaration of Helsinki states that a new intervention should be tested against the current best proven intervention. A placebo arm might be justified only if there is no standard treatment or if there are compelling scientific reasons and the condition is not serious or life-threatening.
B, C, and D are not the primary ethical principles violated by the use of a placebo in this context.
- According to ethical guidelines for research involving minors, which of the following is the most appropriate next step?
Answer: Exclude the adolescent from the study.
The correct answer is B. When conducting research with minors who are old enough to comprehend the study, it is ethically required to obtain their assent in addition to the permission of their parents or legal guardians. Assent is the minor's affirmative agreement to participate. If a minor with decisional capacity refuses to provide assent, their decision must be respected, and they should not be enrolled in the study, even if a parent has given permission. This respects the developing autonomy of the adolescent.
A) Enrolling the adolescent would violate the ethical requirement for assent.
C) While physician consultation can be useful, it does not override the adolescent's refusal to assent.
D) Proceeding with enrollment despite the adolescent's refusal is unethical.
- Investigators plan a phase II trial of a novel hydroxyurea analog for sickle cell disease. They propose recruiting exclusively from a nearby urban clinic that serves predominantly low-income Black patients because the disorder is more common in this population, and they believe recruitment will be easier. Which Belmont principle is most directly at risk of being violated by this recruitment strategy?
Answer: Justice, because it may unfairly concentrate research burdens on a disadvantaged group
Research ethics questions on the USMLE often test your understanding of the three Belmont principles: respect for persons, beneficence, and justice. When you see scenarios involving vulnerable populations or recruitment strategies, immediately consider which principle might be compromised.
The recruitment strategy described raises a justice concern because it concentrates research participation exclusively within a disadvantaged population. While the investigators' reasoning seems practical—sickle cell disease is indeed more common in Black populations—recruiting only from a low-income clinic creates an unfair distribution of research burdens. Justice requires that the benefits and risks of research be fairly distributed across society, not concentrated among those who may have fewer resources or less power to decline participation.
Looking at the wrong answers: B is incorrect because the safety concern about an investigational drug relates to beneficence, but that's not the primary issue with the recruitment strategy itself. C misses the mark because nothing in the scenario suggests patients lack decision-making capacity—assuming they can't provide informed consent based on their demographic characteristics would itself be problematic. D is wrong because this appears to be a phase II trial testing efficacy, and withholding standard therapy from controls would be an issue in any trial design, not specific to this recruitment approach.
Remember that justice violations often involve unfair targeting of vulnerable populations for research participation. When you see exclusive recruitment from disadvantaged communities, consider whether the research burdens are being equitably distributed across society.
- An investigator proposes a retrospective chart review of patients admitted for asthma exacerbations over the last 5 years. The study will record age, sex, and aggregated medication data; all names and medical record numbers will be removed before analysis. According to federal regulations, which Institutional Review Board (IRB) determination is most appropriate?
Answer: The project qualifies for exemption because the data are existing and will be recorded in a de-identified manner
When you encounter questions about research ethics and IRB requirements, focus on understanding the federal regulations that govern human subjects research, particularly the Common Rule and HIPAA requirements.
This retrospective chart review qualifies for IRB exemption under federal regulation 45 CFR 46.104(d)(4), which covers research involving existing data that cannot identify subjects. Since all names and medical record numbers will be removed before analysis, creating a truly de-identified dataset, the study meets exemption criteria. The key is that the data already exists and will be completely stripped of identifiers before the researcher accesses it for analysis.
Option B is incorrect because while the original medical records contain protected health information (PHI), the removal of all identifiers before analysis means the researcher never actually handles PHI. Once properly de-identified, the data is no longer considered PHI under HIPAA regulations.
Option C misunderstands expedited review requirements. While the inclusion of minors does require special consideration in many studies, expedited review is typically for research involving minimal risk with identifiable data. The de-identification here eliminates the need for expedited review based solely on minor participation.
Option D reflects a common misconception about secondary data use. Re-consent is not required when data is properly de-identified for research purposes, as there's no way to link findings back to individual patients.
Remember this pattern: De-identified existing data typically qualifies for IRB exemption, while identifiable data requires either expedited or full review depending on risk level. The presence or absence of identifiers is often the key determining factor.
- This scenario raises a significant ethical concern related to the principle of justice, specifically regarding which of the following issues?
Answer: The lack of post-trial access to beneficial treatment
The correct answer is B. The principle of justice requires that the benefits and burdens of research be distributed equitably. In this case, the population of the low-income country is bearing the burdens and risks of the research. However, if the benefits of that research (the effective drug) are not made reasonably available to them after the trial, they have been exploited for the benefit of wealthier populations. This is a key concern in international research, and ethical guidelines increasingly call for provisions for post-trial access.
A, C, and D are all important ethical considerations in any trial, but the core issue of justice highlighted by the vignette is the lack of post-trial access.
- The involvement of prisoners in this research requires special ethical consideration primarily because this population is considered vulnerable to which of the following?
Answer: Exploitation
The correct answer is A. Prisoners are considered a vulnerable population in research ethics because their incarceration inherently curtails their autonomy and freedom. This creates a risk that they may feel coerced or unduly influenced to participate, for instance, by the hope of preferential treatment or out of boredom, making them susceptible to exploitation. Federal regulations (45 CFR 46, Subpart C) provide additional protections for prisoners as research subjects to mitigate this risk.
B) While physical harm is a risk in any study, it is not the primary reason prisoners are a specially protected class.
C) Confidentiality is an important consideration for all participants, not just prisoners.
D) Therapeutic misconception (the belief that the primary purpose of research is to provide personal treatment) can affect any participant, not just prisoners.
- Which of the following is the most likely determination the IRB will make regarding this study protocol?
Answer: The study is exempt from IRB review.
The correct answer is B. Research involving the collection or study of existing data is eligible for exemption from IRB review and the requirement for informed consent if the information is recorded by the investigator in such a manner that subjects cannot be identified, directly or through identifiers linked to the subjects. Since the researcher is only using de-identified data and cannot link it back to individuals, the study poses no more than minimal risk and qualifies for an exemption.
A) Full board review is for studies with greater than minimal risk.
C) Expedited review is for minimal risk studies that do not qualify for exemption.
D) Requiring informed consent would be necessary if identifiable private information were being used.
- This situation raises the most significant concern for which of the following ethical issues?
Answer: A conflict of interest
The correct answer is B. A conflict of interest arises when a researcher's private interests, such as financial gain, may compete with their professional obligations to conduct objective research and ensure patient welfare. The principal investigator's stock ownership creates a financial incentive that could bias their judgment in data collection, interpretation, and reporting of adverse events, potentially compromising the integrity of the research and the safety of the participants.
A) Clinical equipoise refers to the genuine uncertainty about the comparative effectiveness of the treatments being tested, which is not the primary issue described.
C) There is no information in the vignette to suggest that patient confidentiality has been breached.
D) Inequitable subject selection concerns the principle of justice and fair distribution of research burdens and benefits, which is not the main issue here.
- Investigators design a randomized controlled trial comparing two standard antihypertensive medications with similar efficacy profiles. They justify the study based on uncertainty in the medical community about which drug should be first-line. Which ethical concept supports the use of randomization in this setting?
Answer: Clinical equipoise requiring genuine uncertainty regarding comparative benefits
Research ethics questions on the USMLE often test your understanding of when clinical studies are justified and what ethical principles guide study design. When you see a scenario about randomization in clinical trials, think about what makes it ethical to randomly assign patients to different treatments.
Clinical equipoise is the foundational ethical concept that justifies randomization in clinical trials. It exists when there is genuine uncertainty in the medical community about which treatment is superior. In this scenario, both antihypertensive medications have "similar efficacy profiles" and there's "uncertainty in the medical community" about which should be first-line therapy. This genuine uncertainty makes it ethical to randomly assign patients to either treatment, since we honestly don't know which is better. Choice A correctly identifies this principle.
Choice B describes therapeutic privilege, which involves physicians withholding information from patients when disclosure might cause harm - this doesn't relate to randomization ethics. Choice C mentions noninferiority studies, which test whether a new treatment is "acceptably close" to standard therapy, but this scenario compares two existing standard treatments of similar efficacy. Choice D incorrectly focuses on placebo deception, but neither group receives a placebo here - both receive active, standard treatments.
Remember that clinical equipoise is what makes randomization ethical - you can only randomly assign treatments when there's genuine scientific uncertainty about which is better. Without equipoise, randomization would be unethical because you'd be knowingly giving some patients inferior treatment. Look for scenarios describing "uncertainty" or "similar efficacy" as clues pointing to equipoise.
- A principal investigator analyzing interim data notes that the primary end point of his randomized clinical trial has not been met. Fearing difficulty obtaining future grants, he decides not to submit the negative findings for publication. Which of the following best describes the ethical violation involved?
Answer: Suppression of data distorts the scientific record and breaches the investigator's duty of beneficence to future patients
Research ethics questions on the USMLE often test your understanding of fundamental principles like beneficence, autonomy, justice, and non-maleficence, along with concepts of scientific integrity and publication bias.
The correct answer is A because suppressing negative research results violates two key ethical principles. First, it distorts the scientific record by creating publication bias—when only positive studies are published, the medical literature presents a skewed view of treatment effectiveness. This misleads future researchers, clinicians, and patients about what truly works. Second, it breaches the investigator's duty of beneficence to future patients, who deserve access to complete information about treatments, including knowledge about what doesn't work. The investigator has an ethical obligation to contribute to the collective medical knowledge that benefits society.
Option B is incorrect because informed consent violations relate to not properly informing subjects about study risks before participation, not about publication decisions made after the study. Option C misunderstands plagiarism, which involves stealing or misrepresenting someone else's work as your own—withholding your own data isn't plagiarism. Option D incorrectly applies the principle of justice, which concerns fair distribution of benefits and burdens in research, not confidentiality of results.
Remember that publication bias is a major concern in evidence-based medicine. When you see ethics questions about research, consider how the action affects the integrity of the scientific record and the investigator's duties to future patients, not just current study participants.
- To ethically enroll this patient, the researcher must obtain informed consent from the daughter and which of the following from the patient?
Answer: Assent, to the extent of his ability
The correct answer is B. For adults with diminished capacity, the ethical principle of respect for persons requires that researchers seek their assent to participate in research, in addition to obtaining informed consent from their legally authorized representative. Assent is a person's affirmative agreement to participate, and it should be sought even if the individual cannot provide legally valid informed consent. It respects their autonomy to the greatest extent possible. Refusal to assent should generally be honored.
A) A signature without understanding does not constitute valid consent or assent.
C) A commitment to complete the study is not the core ethical requirement for enrollment.
D) While an evaluation of capacity is important for determining who should provide consent, it is the patient's assent that is also required.
- The principal investigator's action is an example of which of the following forms of research misconduct?
Answer: Falsification
The correct answer is C. Research misconduct is broadly defined as fabrication, falsification, or plagiarism. Falsification is manipulating research materials, equipment, or processes, or changing or omitting data or results such that the research is not accurately represented in the research record. By selectively removing data points that do not support the desired outcome without a valid, pre-specified justification, the PI is falsifying the results.
A) Plagiarism is using another's work without credit.
B) A conflict of interest is a situation that could bias judgment, but the action itself is falsification.
D) There is no indication of a breach of confidentiality.
- A 9-year-old boy with cystic fibrosis is being considered for enrollment in a clinical trial of a new inhaled antibiotic. The investigators explain the study to both the child and his parents. The parents agree, but the boy becomes visibly upset and repeatedly says he does not want additional treatments. According to ethical guidelines for pediatric research participation, which of the following actions is most appropriate?
Answer: Do not enroll the boy because his dissent should be respected despite parental permission
When you encounter questions about pediatric research ethics, focus on the key principle that children deserve special protections beyond standard informed consent procedures. Pediatric research requires both parental permission AND the child's assent when developmentally appropriate.
The correct answer is A because ethical guidelines clearly state that a child's dissent (refusal to participate) should be respected, even when parents have given permission. A 9-year-old is developmentally capable of understanding basic aspects of research participation and expressing meaningful preferences. His repeated verbal objections and visible distress demonstrate clear dissent that investigators must honor.
Option B is incorrect because parental authority in research contexts has important limitations - parents cannot override their child's explicit refusal to participate in non-therapeutic research. Option C is wrong because seeking court intervention to force research participation violates fundamental ethical principles; courts don't override children's dissent for research enrollment. Option D represents an attempt to coerce or manipulate the child's decision through incentives, which is ethically inappropriate and doesn't address his fundamental objection to additional treatments.
This scenario differs from emergency medical treatment where parental consent might override a child's objections. Research participation is voluntary and offers no guaranteed direct benefit to this specific child, making the child's autonomous refusal paramount.
Remember for Step 1: In pediatric research questions, child dissent always trumps parental permission. Look for scenarios where children express clear refusal - their "no" means no, regardless of what parents want.
